Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
67 hedge funds and large institutions have $755M invested in Avidity Biosciences in 2020 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
29% more funds holding
Funds holding: 52 → 67 (+15)
8% more capital invested
Capital invested by funds: $702M → $755M (+$53.6M)
4.13% more ownership
Funds ownership: 67.87% → 72% (+4.1%)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$26.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1M |
| 3 |
BlackRock
New York
|
+$20.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.33M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$11.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.72M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$7.11M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.64M |
| 5 |
Millennium Management
New York
|
-$6.39M |
RNAM Hedge Fund Activity: Q3 2020 in Review
67 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2020, worth a combined $755M — up 7.6% from $702M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RNAM positions and 16 closed out — a net gain of 15 holders — while 12 added to existing stakes and 15 trimmed.
The largest buyer was Federated Hermes, adding an estimated $26.1M. The largest seller was Deerfield Management, cutting an estimated $11.6M.
- 67 institutional investors held Avidity Biosciences (RNAM) as of Q3 2020, up from 52 in Q2 2020.
- Funds reported $755M of Avidity Biosciences stock for Q3 2020, up 7.6% quarter-over-quarter.
- 31 funds opened new Avidity Biosciences positions in Q3 2020 and 16 closed out, a net change of +15 holders.
- The largest Avidity Biosciences buyer in Q3 2020 was Federated Hermes, an estimated $26.1M added.
- The largest Avidity Biosciences seller in Q3 2020 was Deerfield Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2020.